Pharma Forum: Oct 14, 2024

1. Mubadala's KELIX Bio Acquires Four Pharma Assets KELIX Bio, a subsidiary of Mubadala, acquired four pharmaceutical assets from GlobalOne Healthcare Holdings (GHH), strengthening the UAE’s life sciences sector. The acquisition is part of a strategic effort to position the UAE as a leader in global pharma and life sciences, supporting the country's ambition for economic diversification.

   Full Story​ emirates247

   
   

2. Pfizer, BioNTech Halt Development of Flu-COVID Combo Vaccine Pfizer and BioNTech have paused the development of their combination flu and COVID-19 vaccine after struggling with challenges in clinical trials. This comes as part of ongoing adjustments within the vaccine market post-pandemic, where demand has shifted. biopharmadive

   
   

3. Novo Nordisk’s GLP-1 Success in New Therapeutic Areas Following the success of weight-loss drugs like Wegovy, Novo Nordisk is exploring additional uses of GLP-1 agonists in conditions such as Polycystic Ovary Syndrome (PCOS), potentially providing new treatment options for a challenging condition. biopharmadive

   
   

4. Bayer Wins Roundup Legal Battle in the U.S. Bayer achieved a significant legal victory over claims that its Roundup weedkiller causes cancer, with the court ruling in its favor. This has boosted Bayer’s shares and market confidence, providing relief to the company amidst ongoing litigation challenges. biopharmadive

   
   

5. FDA Clears Gilead’s Liver Disease Drug Gilead has received FDA approval for a new treatment targeting liver diseases, following its $4.3 billion acquisition of a biotech company. The approval highlights the importance of strategic acquisitions in expanding treatment pipelines for high-impact diseases. biopharmadive